Tag Archive for: HealthCap

SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT

/in

Financing co-led by Forbion, HealthCap and new investor Bioqube Ventures Funds will be used for pivotal trial of potential best-in-class, next-generation treatment for Tenosynovial Giant Cell Tumour Dublin, Ireland and Oxford, UK, 22 April 2024: SynOx Therapeutics Limited (“SynOx” or the “Company”), the late-stage clinical biopharmaceutical company, is pleased to announce the close of a […]

Read more

Novo Holdings participates in Hemab Therapeutics $135M Series B Financing

/in

Hemab Therapeutics is a clinical-stage biotechnology company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders Funding enables completion of ongoing Phase 1/2 study of bispecific antibody HMB-001 in Glanzmann Thrombasthenia, initiation of pivotal studies, start and conclusion of Phase 1/2 study of HMB-VWF in von Willebrand Disease, as well as future […]

Read more

How Early-stage VCs are Adjusting in a Bear Market

/in

As part of a panel session, hosted by Stephen Hansen, at the Anglonordic Life Science conference on 5 May, Optimum’s clients explored the latest dynamics of syndicate building for early-stage VCs.

Read more

In Vivo’s 30 ‘Rising Leaders’ Announced

/in

The 3rd annual listing of In Vivo’s ‘Rising Leaders’ has landed! Optimum is thrilled to see our brilliant clients from M Ventures, INKEF Capital, BioQube, Healthcap and Octarine recognised alongside other leading entrepreneurs and innovators in healthcare, from all across the globe. The 30 people spotlighted have been recognized for bringing something new to the […]

Read more

What Next After A Year Of Innovation And Growth?

/in

As part of its ‘Pharma Outlook for 2022’, leading healthcare publication, In Vivo, explored the outlook for US and EU venture capital funding in biopharma.  Asking whether the sector can keep the momentum going for investments, it drew on the experience and insight of prominent investors [many among them our clients,] to provide comment on […]

Read more